Search results
Results from the WOW.Com Content Network
The liver is the main site of drug metabolism and the drug is metabolized by glucuronidation, hydroxylation and N-dealkylation. The metabolites are mainly excreted in the urine. [24] Letrozole has a standard daily dose of 2,5 mg and the drug has around 99,9% oral bioavailability. That means that the drug is absorbed fast and entirely.
Letrozole, sold under the brand name Femara among others, is an aromatase inhibitor medication that is used in the treatment of breast cancer for post-menopausal women. [1]It was patented in 1986 and approved for medical use in 1996. [4]
As such, historically each province has managed their own pharmaceutical system, from formularies to public prescription drug programs, in different ways. [3] This meant that health technology assessments were performed independently by a patchwork of organizations, with some provinces, like Quebec and British Columbia having their own in-house ...
Progestins (progesterone-like drugs) such as megestrol acetate and medroxyprogesterone acetate have been used for the treatment of hormone-responsive, advanced breast cancer, endometrial cancer, and prostate cancer. Progestins are also used in the treatment of endometrial hyperplasia, a precursor to endometrial adenocarcinoma. The exact ...
One of Pritchard's self-proclaimed "eureka" moments was in a clinical trial concerning the use of the drug letrozole as an adjuvant therapy in postmenopausal women who had taken tamoxifen for five years as a primary breast cancer treatment. Letrozole is an aromatase inhibitor that reduces estrogen production, which is necessary for tumor growth ...
The drug also counteracts gynecomastia as well as fat and water retention following excessive aromatase production due to testosterone doping. [17] It is also used by steroid users to lower female sexual horomone levels following a cycle of steroids, often called a "post-cycle therapy", it is also used alongside Selective estrogen receptor ...
The Controlled Drugs and Substances Act (French: Loi réglementant certaines drogues et autres substances) is Canada's federal drug control statute. Passed in 1996 under Prime Minister Jean Chrétien's government, it repeals the Narcotic Control Act and Parts III and IV of the Food and Drugs Act, and establishes eight Schedules of controlled substances and two Classes of precursors.
The drug was reviewed and approved under the Food and Drug Administration’s (FDA) accelerated Priority Review and Breakthrough Therapy designation programs on February 3, 2015, as a treatment (in combination with letrozole) for patients with estrogen receptor positive (ER+) advanced breast cancer. [10] This was an accelerated approval. [11]